News
Hosted on MSN1mon
Seismic Therapeutic doses first healthy participant cohort in Phase I trial of S-1117US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase I trial of S-1117, a treatment for autoimmune diseases. The double ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback